Allergy & Immunology

Find out more about peanut oral immunotherapy as a promising treatment for young children in Australia with peanut allergy.

These findings support the effectiveness of herbal-based emollients plus in managing atopic dermatitis, extending beyond simple hydration to actively aiding in barrier repair and symptom relief.

The BTCRC LUN 16-081 trial is the first to evaluate a shorter, six-month course of consolidation immunotherapy using nivolumab alone or in combination with ipilimumab.

The study found that patients receiving the AR-PRISE intervention experienced significant improvements in symptom control, particularly over the longer term.

The study also highlighted the diagnostic challenges posed by unreliable histories and overlapping symptoms from infection-related exanthems.

Peanut oral immunotherapy (POIT), which involves gradually increasing exposure to peanut protein, has shown promise, successfully desensitising 50–70% of patients.

A recent landmark study is the first randomised, controlled trial to show clinical benefits of an allergy app for SAR sufferers.

In a new study, researchers identified a specific immune cell type, CD4+ T follicular helper (Tfh) cells producing IL-21 and IFN-γ, as a key driver of ICI-T1DM.